Offstream
news

A trial of a plant-based COVID-19 vaccine conducted by GSK and Medicago shows an overall 71% efficacy against disease caused by the predominant SARS-CoV-2 variants of concern observed during most of 2021, and 75% efficacy specifically against disease caused by Delta. The study excludes the Omicron variant, which was not in circulation at the time of the clinical trials.
2021-12-7

The Medicines and Healthcare products Regulatory Agency approves GSK and Vir Biotechnology's sotrovimab antibody treatment, after a clinical trial found that the treatment reduced the risk of hospital admission and death by 79% in vulnerable adults if administered within five days of symptoms developing.
2021-12-2

The Health Ministry panel committee approve the usage of the single-dose monoclonal antibody-based treatment sotrovimab developed by GlaxoSmithKline and Vir Biotechnology to treat mild and moderately-ill COVID-19 patients.
2021-09-27

GlaxoSmithKline and the German biotech firm CureVac sign an agreement worth 150 million euros ($180.7 million) to develop a vaccine to counter many variants of SARS-CoV-2. The vaccine, which is subject to regulatory approval, is expected to be introduced in 2022.
2021-02-3

GlaxoSmithKline and Sanofi announces that they will start vaccine trials.
2020-09-3

The United States government is expected to pay $2.1 billion to Sanofi and GlaxoSmithKline to try to develop and deliver 100 million doses of their potential COVID-19 vaccine.
2020-07-31

China fines Glaxosmithkline US$490 million for its alleged involvement in a bribery scandal.
2014-09-19

Pharmaceutical giant GlaxoSmithKline agrees to sell its thrombosis drug brands to Aspen Pharmacare.
2013-09-30

British pharmaceutical company GlaxoSmithKline admits that some of its senior executives in China appear to have broken the law as part of a bribery scandal.
2013-07-22

GlaxoSmithKline settles the largest healthcare fraud case in US history for $3 billion dollars.
2012-07-2